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Dietary Inclusion of Colicin E1 Is Effective in Preventing Postweaning
Diarrhea Caused by F18-Positive Escherichia coli in Pigs
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With worldwide concern over the use of antibiotics in animal agriculture and their contribution to the spread
of antibiotic resistance, alternatives to conventional antibiotics are needed. Previous research in our labora-
tories has shown that colicin E1 is effective against some Escherichia coli strains responsible for postweaning
diarrhea (PWD) in vitro. In this study we examined the efficacy of the dietary inclusion of colicin E1 in
preventing experimentally induced PWD caused by F18-positive enterotoxigenic E. coli in young pigs. Twenty-
four weaned pigs (23 days of age), identified by genotyping to be susceptible to F18-positive E. coli infections,
were individually housed and fed diets containing 0, 11, or 16.5 mg colicin E1/kg diet. Two days after the start
of the trial, all animals were orally inoculated with 1  109 CFU of each of two F18-positive E. coli strains
isolated from pigs with PWD. The dietary inclusion of colicin E1 decreased the incidence and severity of PWD
caused by F18-positive enterotoxigenic E. coli and improved the growth performance of the piglets. Addition-
ally, the reduced incidence of PWD due to dietary colicin E1, lowered the levels of expression of the genes for
interleukin 1 and tumor necrosis factor beta in ileal tissues from these animals. The dietary inclusion of
colicin E1 may be an effective alternative to conventional antibiotics in the diets of weaning pigs for the
prevention of PWD caused by F18-positive enterotoxigenic E. coli.
Postweaning diarrhea (PWD) is a serious threat to the eco-
nomic success of the swine industry both due to losses as a
result of mortalities and due to the reduced growth perfor-
mance of surviving pigs. It is estimated that 50% of piglet
mortality due to diarrhea is attributable to the causative agent
of PWD, enterotoxigenic Escherichia coli (ETEC) (18). The
ETEC strains most commonly associated with PWD possess
either the F4 or the F18 fimibrial type (11, 39). As a result of
the significant impact that F18-positive ETEC and other bac-
terial infections can have on pig production, prophylactic an-
tibiotics are frequently included in the diets of young pigs in an
attempt to prevent ETEC colonization and the resulting PWD.
An estimated 78% of large swine farms in the United States
include subtherapeutic concentrations of antibiotics in the di-
ets for young pigs (36). Despite the use of antibiotic prophy-
laxis, 40.7% of these farms reported the occurrence of diarrhea
caused by E. coli infections (36). The lack of the effective
prevention of PWD with the use of prophylactic antibiotics is
not surprising because of the frequency and spectrum of anti-
biotic resistance seen among ETEC strains (7, 23, 25). It is
expected that antibiotic resistance will further increase among
these strains, based on the overall increase in resistance to
antibiotics by ETEC strains over the last 20 years (25).
With worldwide concern over the use of prophylactic anti-
biotics in animal agriculture and its contribution to the spread
of antibiotic resistance (12, 34, 38), the development of alter-
natives to conventional antibiotics is urgently needed to pro-
tect swine from these E. coli infections. Public concerns sur-
rounding the antibiotic resistance issue led to the elimination
of prophylactic antibiotic use in animal agriculture in Denmark
(20, 34). This cessation of the use of prophylactic antibiotics in
pig production caused increases in the rate of PWD and a
30% increase in piglet mortality (34). These infections led to
a large increase in veterinarian-prescribed antibiotic use in
Denmark’s swine industry (35). The switch from growth-
promoting or prophylactic antibiotic usage to veterinarian-
prescribed therapeutic usage resulted in only a very modest
reduction, if any, in total antibiotic usage in Denmark’s
swine industry (35). In order to realize a true reduction in
antibiotic use in animal agriculture, effective alternative
therapies must be developed.
A potential alternative to conventional antibiotics that holds
a great deal of promise are colicins. Colicins are a class of
bacteriocins produced by and effective against E. coli and
closely related bacteria (14). Pore-forming colicins, such as
colicin E1, bind to their target bacteria and kill them by dis-
rupting the ionic gradient of the cell (14). These proteins are
particularly attractive for use as an alternative to conventional
antibiotics for the control of E. coli-caused PWD for several
reasons. We have previously shown them to be effective against
ETEC strains isolated from pigs with PWD in vitro (33), and
other work has demonstrated that colicin E1 is effective against
a wide range of E. coli strains (22, 27, 30). They are also not
related to any antibiotics that are currently being used in hu-
man medicine. Additionally, colicins would not be absorbed
intact by the animals, thereby eliminating concerns over the
presence of antibiotic residues in meat, and colicins could be
effective at concentrations low enough to not significantly alter
the nutrient density of the diet. The objective of this study was
to determine the efficacy of the dietary inclusion of colicin E1
in preventing PWD due to F18-positive ETEC.
* Corresponding author. Mailing address: Department of Animal
Science, North Carolina State University, Campus Box 7621, 226A
Polk Hall, Raleigh, NC 27695. Phone: (919) 513-1512. Fax: (919)
515-6884. E-mail: chad_stahl@ncsu.edu.
 Published ahead of print on 27 August 2007.
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MATERIALS AND METHODS
Colicin production. Colicin E1 was produced and purified to homogeneity by
the method of Stahl et al. (33). Briefly, a colicin E1-producing strain of E. coli
was grown in LB medium, and colicin production was induced by the addition of
mitomycin C (EMD Biosciences, San Diego, CA) to the medium. The colicin E1
was purified from the cell-free supernatant by ion-exchange chromatography,
first by using DEAE cellulose (Sigma-Aldrich, St. Louis, MO) and then by
further purifying the protein with Q Sepharose (GE Healthcare, Piscataway, NJ).
The purity of the colicin E1 used in this study has been visualized by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and is estimated to be over
95% pure (30).
ETEC challenge strains. Escherichia coli F18-producing strains 2144 (O147:
NM, where NM indicates nonmotile) and S1191 (O139) were used as challenge
strains. Strain S1191 was isolated from a pig with edema disease, produces
heat-stable toxins (ST) STa and STb and Shiga toxin 2e, and is chloramphenicol
resistant. Strain 2144 was a field isolate that was made nalidixic acid resistant and
produces the toxins STa and STb. Both strains were grown overnight as pure
cultures in LB medium at 37°C with shaking. They were then individually diluted
to an optical density at 600 nm (OD600) of 0.1 in fresh LB medium and allowed
to grow to an OD600 of 1. The cultures were then centrifuged at 4,000  g for
10 min at 4°C. The bacterial pellets were resuspended in 20% dextrose and 5%
nonfat dry milk. The challenge dose consisted of an equal amount of each strain
and was determined by serial dilution and plating to provide a total 2  109
CFU/0.5 ml oral dose.
Animals. All of our protocols involving animals were approved by the Insti-
tutional Animal Care and Use Committee of Iowa State University. The 24
barrows (castrated pigs) used were obtained from the Iowa State University
Swine Nutrition Farm and were determined to be susceptible to F18-positive E.
coli infections based on the restriction fragment length polymorphism test de-
scribed by Frydendahl et al. (15). Briefly, genomic DNA was purified (DNeasy
kit; QIAGEN, Valencia, CA) from pig tail clippings, and primers (forward
primer, TTGGGAACCAGATGGGACAGTATG; reverse primer, CCCGCCA
AGGAGCGTGCCTGTCTA) were used to amplify a 162-bp section of the
1,2-fucosyltransferase enzyme gene (ECF18R) by PCR (26). The 162-bp PCR
product was then digested with HhaI (New England Biolabs, Ipswich, MD), and
the polymorphism was determined by size comparison on a 3% agarose gel.
Pigs were weaned at 17 days of age and allowed to adjust to solid food
(TechStart 17-25; Kent Feeds, Muscatine, IA). At 21 days of age, the pigs (n 
8) were allotted into treatment groups on the basis of their body weights and
were transferred to individual pens. The pigs were given 2 days to adjust to
individual housing before the experimental diets were fed. The basal diet for all
of the experimental diets was corn and soy based and contained no animal
products (26% crude protein, 3.51 kcal/kg of diet). This diet met or exceeded the
nutrient requirements of these pigs, based on the 1998 recommendations of the
National Research Council (29). Either 0 (control), 11, or 16.5 mg of purified
colicin E1 (supplied at 10 mg/ml in 10 mM Tris, pH 7.6) was added per kg to the
basal diet (TestDiet; Purina, Richmond, IN), and the diets were then pelleted at
low temperature. The pelleted rations were provided to the pigs twice daily at a
rate which exceeded the consumption for each animal (approximately 500 g/day).
The unconsumed feed was weighed daily and feed intake was determined.
After the animals received the experimental diets for 2 days, all animals were
orally inoculated with the two F18-positive ETEC strains and their fecal scores
were recorded. Fecal scores (0, dry, hard, and well-formed feces; 1, soft but
formed feces; 2, pasty feces green or brown in color; 3, viscous feces light in color,
episodic; 4, fluid feces light in color, episodic; 5, watery feces, continuous) were
determined twice daily after the bacterial challenge. Fecal samples were obtained
2 days prior to the ETEC challenge and daily after the challenge by inserting a
10-l fecal loop (Fisher Scientific, Pittsburgh, PA) into the rectum. These sam-
ples were immediately diluted in 5 ml of sterile phosphate-buffered saline. Serial
10-fold dilutions (up to 1:100,000) were plated onto MacConkey (MAC; Difco,
Franklin Lakes, NJ), MAC-chloramphenicol, and MAC-nalidixic acid agar plates
for CFU determination. Our limit of detection for the fecal samples was 10,000
CFU/g. Four days postchallenge, all pigs were euthanized by captive bolt, and
tissue samples were collected. Ileal sections (approximately 10 cm each) were
collected from each pig for RNA extraction and E. coli enumeration. Addition-
ally, rectal and cecal contents were collected for E. coli enumeration.
Gene expression. Isolation of RNA from the ileum was performed by using a
whole ileal homogenate and an RNeasy kit (QIAGEN). Genomic DNA was
eliminated from the extracted total RNA by using the DNA-free kit from Am-
bion (Austin, TX), according to the manufacturer’s instructions. The RNA was
reverse transcribed with Superscript III reverse transcriptase (Invitrogen Life
Technologies, Carlsbad, CA), and the RNA was removed from the resulting
cDNA by incubation with E. coli RNase H (Invitrogen), according to the man-
ufacturer’s instructions. The cDNA concentrations were determined by using a
Quant-it kit (Invitrogen), and the cDNA samples were then stored at80°C until
analysis by real-time PCR. The levels of interferon (IFN), interleukin 10 (IL-10),
IL-8, tumor necrosis factor alpha (TNF-), tumor necrosis factor beta (TNF-),
IL-1, and inducible nitric oxide synthase (iNOS) mRNA were determined
semiquantitatively by real-time PCR with a the MyiQ single-color real-time PCR
detection system and SYBR green (Bio-Rad Laboratories; Hercules, CA). The
thermal cycling conditions included 45 cycles of 30 s of melting at 95°C, followed
by 30 s of annealing and extension at 65°C. Following amplification, all samples
were subjected to a melting curve analysis to ensure that only a single product
was formed. Primer oligonucleotides (Table 1) were designed by using Primer-
Quest software, available from Integrated DNA Technologies (Coralville, IA).
All primer sets were validated to amplify only the sequence of interest and to do
so in a linear fashion over a 2-log range of cDNA concentrations. The data for
all samples were normalized to the cDNA concentration prior to statistical
analysis.
Bacterial enumeration. The enumeration of E. coli from the ileal mucosa,
cecal content, and rectal content samples was performed as follows. The samples
were weighed, diluted 1:2 with buffered peptone water, and placed in a stom-
acher blender (Stomacher 80; Seward, Worthing, United Kingdom) for 30 s. The
samples were then serially diluted over a 4-log range at a 1:200 starting dilution.
Ten microliters of each dilution was plated in duplicate on MAC, MAC-chlor-
amphenicol (30 g/ml), and MAC-nalidixic acid (50 g/ml) agar plates. The
plates were incubated for 16 h at 37°C, and the countable dilution was then
recorded. Our limit of detection for these samples was 1,000 CFU/g.
Statistical analysis. Statistical analysis of the data was performed with Statis-
tical Analysis Software, version 9.1 (SAS, Cary, NC), by the general linear
models procedure for comparison of least-squares means. Treatment was con-
sidered a fixed effect, and for growth parameters, initial body weight was used as
a covariate in the analysis. For bacterial enumeration data, when the counts were
below our limit of detection, a value of 1 CFU/g less than our limit of detection
was ascribed prior to analysis. Statistical significance was set at  equal to 0.05,
and trends are discussed at an  value of 0.1.
RESULTS
Fecal scores. Prior to bacterial challenge, there was no in-
dication of diarrhea or loose stools among any of the pigs.
TABLE 1. Primer sequences for semiquantitative real-time PCR
analysis of intestinal gene expression
mRNA Directiona Primer sequence
iNOS F GGACGTACGAAGTGACCAACC
R GAACGTACGAAGTGACCAACC
IL-1 F TGAAGAAGAGCCCATCGTCCT TGA
R TGCACAAAGCTCATGCAGAACACC
TGF-b F AGGCCGTACTGGCTCTTTACAACA
R TTGGTTGCCGCTTTCCACCATTAG
IL-10 F AAGACGTAATGCCGAAGGCAGAGA
R TGCTAAAGGCACTCTTCACCTCCT
IFN F ATGACTTCCAAACTGGCTGTTGCC
R TATGCACTGCGATCGAAGTTCTGC
IL-8 F ATGACTTCCAAACTGGCTGTTGCC
R TATGCACTGGCATCGAAGTTCTGC
TNF- F GCCCACGTTGTAGCCAATGTCAAA
R GTTGTCTTTCAGCTTCACGCCGTT
TNF- F AGATCAGCTGTCCAGACACACAGA
R TAGAGCGAAGGCTCCAAAGAAGAC
a F, forward; R, reverse.
b TGF-, transforming growth factor .
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There were no differences in fecal scores between the treat-
ment groups until 48 h postchallenge. At this point the group
fed the control diet had a mean fecal score of 2.38, which
tended to be higher (P 	 0.06) than that for the group fed the
16.5-mg colicin E1/kg diet (mean score, 0.5) (Fig. 1). Over the
entire study, the control group had a significantly higher (P 	
0.05) average fecal score than the high-dose (16.5-mg/kg) co-
licin E1 group (2.1 and 0.59, respectively). The low-dose (11-
mg/kg) colicin E1 group also had higher (P 	 0.05) average
fecal scores than the high-dose group, and these were not
significantly different from those for the control pigs. These
differences in group fecal scores were caused by the incidence
of diarrhea (fecal scores, 4) in one, four, and five of the eight
control group pigs 24, 48, and 72 h after ETEC inoculation,
respectively. Among the pigs fed the low dose of colicin E1, no
animals had diarrhea at 24 h postinoculation; however, three
and four pigs had diarrhea at 48 and 72 h postchallenge, re-
spectively. None of the pigs fed the high dose of colicin E1 had
any incidence of diarrhea at any time during the experiment.
Growth performance. The dietary inclusion of colicin E1 had
a significant effect (P	 0.05) on the growth performance of the
pigs in this study (Table 2). From the time of E. coli challenge
until the completion of the study, the pigs fed the control diet
gained an average of 380 g, while the pigs receiving the low and
high doses of colicin E1 in their diets gained 540 and 940 g,
respectively (Table 2). Although the animals fed the control
diet gained the least body weight over the course of the study,
they consumed significantly (P 	 0.05) more feed than either
of the groups fed diets containing colicin E1. The control
group of animals averaged a total consumption of 1.54 kg of
diet, while the pigs treated with the low and high doses of
colicin E1 ate 1.22 kg and 1.44 kg, respectively. Although there
were significant differences in both body weight gain and feed
consumption, there was not a significant difference in feed
conversion efficiency (body weight gain/feed intake) (P	 0.19)
among any of the treatment groups. This was because over the
length of the study two of the pigs in the control group lost
weight (approximately 400 g each) and one pig gained virtually
no weight (less than 10 g) while still consuming feed. This
negative body weight gain resulted in a negative feed conver-
sion efficiency, which resulted in tremendous variation in the
feed conversion efficiency values for this group.
Bacterial enumeration. (i) Fecal cultures. No colonies were
isolated on the agar plates containing either chloramphenicol
or nalidixic acid from any samples prior to the ETEC chal-
lenge. At 24 h postinoculation, the levels of both total coli-
forms and ETEC challenge strain 2144 recovered in the feces
were significantly higher (P 	 0.05) for the control animals
than for both groups of colicin E1-fed pigs (Table 3). There
were no significant differences between the groups in the re-
covery of ETEC strain S1191 at the first day postchallenge, but
on the following day there was a reduction in the high-dose
colicin E1 group compared to that in the controls (P 	 0.05).
By the last day of fecal sampling, the levels of strain S1191 had
dropped below our detection limit for most of the animals, re-
gardless of the dietary treatment (16/24 pigs), and there were no
significant differences in the amount of strain 2144 recovered.
(ii) Tissues. In the ileum, both colicin E1-fed groups aver-
aged lower levels (P 	 0.05) of the S1191 challenge strain and
coliforms compared to those in the controls (Table 4). There
were no significant differences in the recovery of bacteria from
the cecal samples among the groups. Strain S1191 was recov-
ered from samples from only three of the eight animals in the
high-dose colicin E1 group and was recovered from six and
four of the eight animals in the control and the low-dose colicin
E1 treatment groups, respectively. In the rectum, similar levels
of total coliforms and strains 2144 and S1191 were recovered
from the animals in all groups.
Gene expression. The concentration of TNF- mRNA in
ileal tissue was higher (P	 0.06) in the control animals than in
either of the colicin E1-treated groups (Fig. 2). The amount of
IL-1 mRNA was the highest in the group supplemented with
the low dose of colicin E1 (sixfold higher [P 	 0.01] than the
amount in the controls), whereas the group supplemented with
the high dose of colicin E1 had nearly undetectable levels of
IL-1 mRNA (Fig. 2). The levels of expression of both TNF-
and iNOS tended (P	 0.1) to be greater in the control animals
than in the animals receiving the diets with colicin E1 supple-
mentation. There were no significant differences in the con-
centrations of gamma IFN (IFN-
), IL-8, or IL-10 mRNA in
the ileum among any of the groups.
DISCUSSION
We examined the efficacy of colicin E1 in preventing PWD
caused by F18-producing E. coli because this disease has been
estimated to be responsible for as much as 50% of the eco-
nomic losses seen in the production of weaned pigs (19, 36). In
FIG. 1. Effect of dietary inclusion of colicin E1 on incidence of
diarrhea in weaning pigs following an F18-positive enteropathogenic
E. coli challenge. Asterisks, significant differences (P 	 0.05) between
the high-dose group and both the low-dose and the control groups.
TABLE 2. Effect of dietary inclusion of colicin E1 on growth
performance of weaning pigsa
Treatmentb Wt gain (kg) Feed intake(kg) Feed efficiency
d
Control 0.38*c (0.13) 1.539† (0.544) 27.01 (9.55)
Low dose 0.54*,† (0.19) 1.217* (0.424) 2.83 (1.00)
High dose 0.94† (0.33) 1.442* (0.510) 1.94 (0.69)
a The values presented are means (standard errors of the means).
b The control, low-dose, and high-dose treatments contained 0, 11, and 16.5
mg colicin E1/kg of diet, respectively.
c Values within a column not sharing a common symbol are significantly
different (P 	 0.05).
d Feed efficiency is defined as feed intake/weight gain.
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herds with PWD, mortality of up to 2% (21, 37) can be seen
among weaning pigs, but of greater economic significance is
the morbidity and reduction in growth performance of the pigs
that survive these infections. Although there is a need for
alternatives to conventional antibiotics, the development of
compounds that can be used to combat ETEC-associated
PWD is beset with difficulties, including the availability of an
adequate experimental model of ETEC infection. Establishing
a good challenge model for this disease has proven to be
difficult. Madec et al. (24) used four strains of ETEC and
several different dosing methods in six trials with a total of 168
specific-pathogen-free piglets and was able to generate clini-
cally significant, although transient, diarrhea in only 50% of
the animals (24). The use of a viral coinfectious agent, such as
transmissible gastroenteritis or rotavirus, that leads to immu-
nosuppression and intestinal membrane disruption can also
increase experimental ETEC infection rates (1, 9, 16, 28).
While a cochallenge model can increase the rate of success of
experimentally reproducing PWD, it also adds a potential con-
founding effect, particularly if the viral infection alone causes
reduced growth performance. An alternative to the viral coin-
fection model that has also been shown to increase the success
of an ETEC bacterial challenge is modification of the post-
weaning diet. The removal of all animal-based protein sources
from the postweaning diet can increase the susceptibility of the
pigs to ETEC infection due to a transient intestinal inflamma-
tory response (2, 10). Diets designed to be fed to pigs imme-
diately postweaning typically provide over 40% of the total
protein in the diet as protein from animal sources, in part to
help prevent this temporary inflammatory response. However,
due to the higher cost of animal-based protein sources, there is
a constant push to minimize the amount of animal protein
included in pig diets. While both viral cochallenges and dietary
alterations can increase infection rates in experimentally in-
duced PWD models, identifying the genetic susceptibility of
the animals may offer the most efficient way to increase infec-
tion rates in a challenge model. With the use of prescreening
for an F18 receptor polymorphism, the rate of infection can be
increased from 5.9% in pigs with the F18-resistant genotype to
87% in those that are genetically susceptible (15). In our study,
we used only genetically susceptible animals, as well as a wean-
ing diet that contained no animal protein. With this model we
achieved a 75% infection rate in control animals, with no
mortality after 4 days, with no use of viral coinfection, and with
the use of an easily performed one-time oral challenge.
Although our high dose of colicin E1 (16.5 mg/kg of diet)
was able to eliminate all clinical signs of PWD, our low dose of
colicin E1 appeared to be able to slightly delay only the onset
of PWD. The level of reduction of the challenge strains of E.
coli that reached the ileum as a result of dietary colicin E1
TABLE 3. Effect of dietary inclusion of colicin E1 on E. coli levels recovered from the feces of weaning pigs
Postchallenge time
and treatmenta
No. of CFU/gb
Total coliforms E. coli 2144c E. coli S1191d
1 day
Control 1.1  109*e (4.6  108) 1.7  108* (8.8  107) 4.9  107 (4.3  107)
Low dose 1.5  107† (5.6  106) 1.2  106† (3.7  105) 7.4  104 (2.3  104)
High dose 1.3  107† (5.4  106) 3.7  103† (2.5  106) 4.8  104 (7.5  103)
2 days
Control 7.6  108 (2.9  108) 1.6  108 (9.8  107) 4.7  106 (2.7  106)
Low dose 5.0  108 (2.9  108) 9.1  107 (6.7  107) 3.2  106 (3.1  106)
High dose 6.0  108 (5.6  108) 1.9  108 (1.9  108) 2.4  105 (1.4  105)
3 days
Control 8.0  109 (5.3  109) 6.3  109 (6.2  109) 6.6  104 (2.6  104)
Low dose 9.4  109 (7.3  109) 2.9  109 (2.5  109) 3.6  105 (3.6  105)
High dose 2.3  108 (1.1  108) 3.9  107 (3.1  107) 7.5  105 (3.1  105)
a The control, low-dose, and high-dose treatments contained 0, 11, and 16.5 mg colicin E1/kg of diet, respectively.
b The values presented are least-square means (standard errors of the means).
c Escherichia coli strain 2144 is F18 positive, produces the toxins STa and STb, and was made nalidixic acid resistant.
d Escherichia coli strain S1191 is F18 positive, produces the toxins STa and STb and Shiga toxin 2e, and is chloramphenicol resistant.
e Values within a day and a column not sharing a common symbol are significantly different (P 	 0.05).
TABLE 4. Dietary inclusion of colicin E1 affected bacterial recovery in the ileum of weaning pigs
Treatmenta
No. of CFU/gb
Total coliforms E. coli 2144c E. coli S1191d
Control 4.7  108*e (5.3  107) 3.2  108 (1.8  106) 2.7  105* (1.0  103)
Low dose 1.1  108† (9.9  107) 5.6  107 (5.3  107) 1.0  103† (0)
High dose 3.8  107† (1.7  107) 2.7  106 (1.8  106) 2.5  103† (1.0  103)
a The control, low-dose, and high-dose treatments contained 0, 11, and 16.5 mg colicin E1/kg of diet, respectively.
b The values presented are least-square means (standard errors of the means).
c Escherichia coli strain 2144 is F18 positive, produces the toxins STa and STb, and was made nalidixic acid resistant.
d Escherichia coli strain S1191 is F18 positive, produces the toxins STa and STb and Shiga toxin 2e, and is chloramphenicol resistant.
e Values within a column not sharing a common symbol are significantly different (P 	 0.05).
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inclusion may have been the determining factor in the devel-
opment of clinical disease. Colicin-fed animals had signifi-
cantly lower levels (P 	 0.04) of fecal shedding of the strain
2144 challenge bacteria at 1 day postchallenge. While this
suggests that the addition of colicin to the feed significantly
reduced the amount of viable bacteria that reached the distal
end of the small intestine, it also demonstrates that our colicin
dose was not sufficient to completely eliminate the challenge
strains. By the end of the study there were no significant dif-
ferences in the fecal shedding of either challenge strain on the
basis of colicin treatment. We would not anticipate that the
feeding of colicin E1 would have an effect on reducing the col-
onization of the ETEC strains if they reached the ileum in a
viable state, since colicin E1 is highly sensitive to proteolysis (3,
4, 6). It is likely that not all of the E. coli bacteria in our large
challenge dose would be killed by the colicin E1 present in the
digesta prior to the inactivation of the colicin E1 by proteolysis,
but it appears that enough were eliminated as a result of
high-dose colicin E1 supplementation to prevent disease. The
gene expression data also suggest that fewer of the challenge
bacteria were able to cause the inflammatory response leading
to diarrhea in the pigs. This is supported by the lower levels of
expression (P 	 0.05) of IL-1 and TNF- mRNA in the ileal
tissues of pigs fed the high-dose colicin E1 diet compared with
those in the control group. IL-1 is primarily secreted by mac-
rophages and activates lymphocytes during an inflammatory
response, and increases have been associated with E. coli toxin
production (11, 17). While the concentration of IL-1 mRNA
was significantly lower in the ileal tissue of the pigs fed the high
dose of colicin E1 than in the ileal tissue of the control pigs,
pigs in the low-colicin E1-dose group had mRNA levels that
were over sixfold higher than those in the control group. At the
time of tissue collection there was no longer any significant
difference in fecal scores between the low-dose and the control
groups, and this elevated expression may indicate a delay in the
inflammatory response as a result of the challenge bacteria.
This would be reasonable, since there appeared to be a delay
in the onset of PWD in the pigs fed the low dose of colicin E1
compared with the time of onset in the control animals. An
increase in IL-1 gene expression in the intestinal mucosa has
been correlated with enteropathogenic E. coli challenge (16),
although the associated increases in the expression of IL-6,
IL-8, and IL-10 seen by Girard et al. (16) were not noted in our
study. Regardless of the dose, colicin E1 in the diet caused
reduced levels (P 	 0.06) of expression of TNF-. TNF-, also
known as lymphotoxin, is a primary effector of NO production
and is associated with inflammatory responses related to T-cell
recruitment (13). The lower levels of TNF- and IL-1 in the
ileal tissues of pigs fed the high dose of colicin E1 compared
with those in the control animals suggest that colicin E1 was
able to significantly reduce the bacterial load that initially
reached the ileum in these animals, thereby reducing the in-
flammatory response to the ETEC challenge.
While other researchers have examined the efficacy of using
colicin-producing bacterial cultures as probiotics for cattle in
order to reduce E. coli O157 contamination (32), we are the
first, to our knowledge, to examine a purified colicin as a feed
component for the prevention of an ETEC infection. We have
demonstrated with growth performance data, clinical indica-
tors of PWD, and intestinal gene expression that the inclusion
of colicin E1 can prevent experimentally induced PWD. The
efficacy in preventing PWD at a level of dietary inclusion of
16.5 mg/kg of diet suggests that colicin E1 warrants further
evaluation as a potential alternative to conventional antibiotics
for use in weaning pig diets. This protein may also have sig-
nificant implications for human food safety as well, since the
efficacy of colicin E1 against many ETEC strains of concern for
human food safety has been well documented (5, 8, 31).
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